CSF2 and melanoma: Others have combined CpG and GM-CSF with melanoma-associated peptides for vaccination in patients with advanced (stage III–IV) melanoma and have shown it to be a safe and promising strategy, but with poor to moderate clinical results, which were attributed to the presence of local regulatory responses and the exhausted phenotype of tumor infiltrating lymphocytes [16].